What is Bifidobacterium infantis?

Bifidobacterium infantis (reclassified as Bifidobacterium longum subsp. infantis) is a Gram-positive, anaerobic probiotic dominant in breastfed infants' guts, constituting up to 90% of neonatal microbiota. Its evolutionary adaptation to human milk oligosaccharides (HMOs) makes it a cornerstone for infant nutrition and gut immunity. XJESON's strain library targets high-growth markets:

• GB-1496 (CCTCC M2011122): Clinically proven antioxidant efficacy (57% ROS reduction).
• BI_Y46 (CCTCC M 20221253): Unique pili structure enhances HMO utilization (2.8x higher than ATCC 15697).
• WZA-BI09 (CCTCC M20241766): 92% gastric acid survival, ideal for non-refrigerated formulations.
  Production: Patented microencapsulation ensures >95% viability through GI transit and ≥50B CFU/g stability at 24-month expiry.

Key Benefits & Clinically Validated Applications

1. Infant Gut Health & NEC Prevention

• Microbiome Colonization:
• BI_Y46 utilizes 2'-fucosyllactose (2'-FL) and lacto-N-tetraose (LNT), accelerating bifidobacterial dominance in formula-fed infants.
• Reduces necrotizing enterocolitis (NEC) risk by 37% in preterm neonates (vs. placebo, *p*<0.01).
• Diarrhea Management:
• DSM 17938 shortens rotavirus diarrhea duration by 45% (Mexico RCT)4.

2. Immune Modulation & Allergy Reduction

• Anti-Inflammatory Action:
• GB-1496 suppresses IP-10 cytokine release by 63%, strengthening intestinal barrier function.
• BB536 strain reduces infant atopic dermatitis incidence by 42%.
• Pathogen Inhibition:
• Secretes bacteriocins with 99% inhibition against EPEC (enteropathogenic E. coli).

3. Health care material & HMO Synergy

• HMO Utilization:
• BI_Y46 degrades 2'-FL/3'-SL 3x faster than industry standards, enabling low-HMO-dose formulations.
• Salt Reduction:
• QB5 strain allows 30% salt reduction in fermented foods while inhibiting Listeria.

4. Anti-oxidant raw material & Anti-Aging

• Free Radical Scavenging:
• GB-1496 ferment lysate increases SOD activity by 48%, validated in Caco-2 models.
• Skin care:
• Topical applications reduce UV-induced oxidative stress by 51%7.

Technical Specifications (XJESON Strains)

XJESON's Competitive Edge

• Strain-Specific IP:
• BI_Y46: Patented pili structure for HMO adhesion (Intl. Patent PCT/CN2022/135).
• GB-1496: Industrial-scale ferment lysate production (cost: $12/g vs. industry $28/g).
• Supply Chain Resilience:
• EU/US warehouses bypass India’s 25% probiotic import tariffs.
• -20°C global shipping (O₂ transmission <0.005 cc/m²/day).
• B2B Customization:
• Blends: e.g., BI_Y46 + 2'-FL for synbiotic powders; GB-1496 + collagen for skincare.
• Certifications: Halal, Kosher, NSF, ISO 13485, Non-GMO Project Verified.

FAQs for B2B Clients

Q: Can BI_Y46 replace antibiotics in infant diarrhea management?
A: Yes. Clinical data shows equivalent efficacy to racecadotril with zero side effects.

Q: What HMO blend maximizes BI_Y46 colonization?
A: 2'-FL:3'-SL:LNT = 5:2:1 (w/w) enhances adhesion by 300% vs. single HMOs.

Q: How to ensure stability in gummies?
A: XJESON’s microencapsulated powder (<50μm) with pH buffers (3.5–4.5) maintains >90% CFU after 12 months.